valproic acid has been researched along with Child Behavior Disorders in 17 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Child Behavior Disorders: Disturbances considered to be pathological based on age and stage appropriateness, e.g., conduct disturbances and anaclitic depression. This concept does not include psychoneuroses, psychoses, or personality disorders with fixed patterns.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The objectives of this study were to determine whether autistic children taking levetiracetam (1) showed improvement in the areas of aggression, impulsivity, hyperkinesis, and mood instability, and (2) showed a nootropic response." | 5.10 | Levetiracetam in autistic children: an open-label study. ( Rugino, TA; Samsock, TC, 2002) |
| " They responded well to the reduction in dosage or to withdrawal of the apparent causing agent." | 2.49 | [Medication-related oculogyric crises: a description of four cases and a review of the literature]. ( Campistol, J; Darling, A; Perez-Duenas, B; Poo, P, 2013) |
| "Benign myoclonic epilepsy in infancy (BMEI) is a well-defined electro-clinical syndrome, classically associated with a good prognosis." | 1.40 | [Benign myoclonic epilepsy in infancy: natural history and behavioral and cognitive outcome]. ( Carreras-Sáez, I; Domínguez-Carral, J; Fournier-Del Castillo, MC; García-Peñas, JJ; Jiménez-Echevarría, S; Pérez-Jiménez, MÁ, 2014) |
| "Phenobarbital has been shown to offer effective prophylaxis against childhood febrile convulsions." | 1.26 | Sodium valproate versus phenobarbital in the prophylactic treatment of febrile convulsions in childhood. ( Lee, K; Melchior, JC, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (23.53) | 18.7374 |
| 1990's | 4 (23.53) | 18.2507 |
| 2000's | 4 (23.53) | 29.6817 |
| 2010's | 5 (29.41) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shinnar, RC | 1 |
| Shinnar, S | 1 |
| Cnaan, A | 1 |
| Clark, P | 1 |
| Dlugos, D | 1 |
| Hirtz, DG | 1 |
| Hu, F | 1 |
| Liu, C | 1 |
| Masur, D | 1 |
| Weiss, EF | 1 |
| Glauser, TA | 2 |
| Huber-Mollema, Y | 1 |
| Oort, FJ | 1 |
| Lindhout, D | 1 |
| Rodenburg, R | 1 |
| Domínguez-Carral, J | 1 |
| García-Peñas, JJ | 1 |
| Pérez-Jiménez, MÁ | 1 |
| Fournier-Del Castillo, MC | 1 |
| Carreras-Sáez, I | 1 |
| Jiménez-Echevarría, S | 1 |
| Hollander, E | 1 |
| Chaplin, W | 1 |
| Soorya, L | 1 |
| Wasserman, S | 1 |
| Novotny, S | 1 |
| Rusoff, J | 1 |
| Feirsen, N | 1 |
| Pepa, L | 1 |
| Anagnostou, E | 1 |
| Darling, A | 1 |
| Poo, P | 1 |
| Perez-Duenas, B | 1 |
| Campistol, J | 1 |
| Rugino, TA | 1 |
| Samsock, TC | 1 |
| Gérardin, P | 1 |
| Cohen, D | 1 |
| Mazet, P | 1 |
| Flament, MF | 1 |
| Woody, RC | 1 |
| Lee, K | 1 |
| Melchior, JC | 1 |
| Herranz, JL | 1 |
| Arteaga, R | 1 |
| Armijo, JA | 1 |
| Schmidt, A | 1 |
| Darius, J | 1 |
| Brosz, M | 1 |
| Roth, N | 1 |
| Meyer, FP | 1 |
| Kroker, S | 1 |
| Wien, F | 1 |
| Brett, B | 1 |
| Hoare, P | 1 |
| Mann, H | 1 |
| Bhatara, VS | 1 |
| Carrera, J | 1 |
| Graf, WD | 1 |
| Oleinik, OE | 1 |
| Maertens, P | 1 |
| Eder, DN | 1 |
| Pippenger, CE | 1 |
| Ronen, GM | 1 |
| Richards, JE | 1 |
| Cunningham, C | 1 |
| Secord, M | 1 |
| Rosenbloom, D | 1 |
| van Wattum, PJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Childhood Absence Epilepsy Rx PK-PD-Pharmacogenetics Study[NCT00088452] | Phase 3 | 453 participants (Actual) | Interventional | 2004-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
A Confidence Index of 0.60 or higher on the Conners' Continuous Performance Test at the visit at 16 or 20 weeks or at an earlier visit when treatment was discontinued (as long as the discontinuation occurred 1 month or more after the baseline visit and was not due to intolerable adverse events). A Confidence Index of 0.60 corresponds to a 60% probability that the child has clinical attention deficit disorder. (NCT00088452)
Timeframe: First 16-20 weeks of double blind therapy
| Intervention | Participants (Count of Participants) |
|---|---|
| Ethosuximide | 35 |
| Lamotrigine | 25 |
| Valproic Acid | 52 |
Treatment failure was defined as persistence of absence seizures at 12 months of double blind therapy, a generalized tonic-clonic seizure at any time, excessive drug-related systemic toxicity, a moderately severe rash (possibly drug-related), pancreatitis, or increase in the body-mass index of at least 3.0 from baseline, dose-limiting toxicity after a single downward dose modification, or withdrawal initiated by the parent or physician. (NCT00088452)
Timeframe: First 12 months of double blind therapy
| Intervention | Participants (Count of Participants) |
|---|---|
| Ethosuximide | 70 |
| Lamotrigine | 31 |
| Valproic Acid | 64 |
Treatment failure was defined as persistence of absence seizures at week 16 or week 20, a generalized tonic-clonic seizure at any time, excessive drug-related systemic toxicity, a moderately severe rash (possibly drug-related), pancreatitis, or increase in the body-mass index of at least 3.0 from baseline, dose-limiting toxicity after a single downward dose modification, or withdrawal initiated by the parent or physician. (NCT00088452)
Timeframe: First 16-20 weeks of double blind therapy
| Intervention | Participants (Count of Participants) |
|---|---|
| Ethosuximide | 81 |
| Lamotrigine | 43 |
| Valproic Acid | 85 |
1 review available for valproic acid and Child Behavior Disorders
| Article | Year |
|---|---|
[Medication-related oculogyric crises: a description of four cases and a review of the literature].
Topics: Adolescent; Anticonvulsants; Antipsychotic Agents; Aripiprazole; Child; Child Behavior Disorders; Ch | 2013 |
4 trials available for valproic acid and Child Behavior Disorders
| Article | Year |
|---|---|
Pretreatment behavior and subsequent medication effects in childhood absence epilepsy.
Topics: Adolescent; Anticonvulsants; Checklist; Child; Child Behavior Disorders; Child, Preschool; Cross-Ove | 2017 |
Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders.
Topics: Adolescent; Antimanic Agents; Child; Child Behavior Disorders; Child Development Disorders, Pervasiv | 2010 |
Levetiracetam in autistic children: an open-label study.
Topics: Aggression; Anticonvulsants; Autistic Disorder; Cetirizine; Child; Child Behavior Disorders; Child, | 2002 |
Can sodium valproate improve learning in children with epileptiform bursts but without clinical seizures?
Topics: Anticonvulsants; Attention; Child; Child Behavior Disorders; Cross-Over Studies; Double-Blind Method | 2000 |
12 other studies available for valproic acid and Child Behavior Disorders
| Article | Year |
|---|---|
Behavioral problems in children of mothers with epilepsy prenatally exposed to valproate, carbamazepine, lamotrigine, or levetiracetam monotherapy.
Topics: Adult; Anticonvulsants; Carbamazepine; Child; Child Behavior Disorders; Epilepsy; Female; Humans; La | 2019 |
[Benign myoclonic epilepsy in infancy: natural history and behavioral and cognitive outcome].
Topics: Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Child Behavior Disorders; Cognition | 2014 |
Drug treatment of conduct disorder in young people.
Topics: Adolescent; Adrenergic alpha-Agonists; Anticonvulsants; Antipsychotic Agents; Carbamazepine; Central | 2002 |
Recent advances in anticonvulsant management of childhood seizure disorders.
Topics: Anticonvulsants; Carbamazepine; Child; Child Behavior Disorders; Child, Preschool; Clonazepam; Human | 1984 |
Sodium valproate versus phenobarbital in the prophylactic treatment of febrile convulsions in childhood.
Topics: Child Behavior Disorders; Child, Preschool; Female; Humans; Infant; Male; Phenobarbital; Seizures, F | 1981 |
Side effects of sodium valproate in monotherapy controlled by plasma levels: a study in 88 pediatric patients.
Topics: Child; Child Behavior Disorders; Child, Preschool; Digestive System Diseases; Epilepsy; Female; Hair | 1982 |
[The effect of valproic acid monotherapy on behavior and cognitive performance of children with idiopathic generalized epilepsy].
Topics: Adolescent; Anticonvulsants; Child; Child Behavior Disorders; Dose-Response Relationship, Drug; Elec | 1995 |
Self-esteem and behavioural adjustment in children with epilepsy and children with diabetes.
Topics: Adolescent; Carbamazepine; Child; Child Behavior Disorders; Cross-Sectional Studies; Diabetes Mellit | 1994 |
Medications for aggressiveness.
Topics: Aggression; Carbamazepine; Child; Child Behavior Disorders; Clonidine; Electroencephalography; Hallu | 1994 |
Altered antioxidant enzyme activities in children with a serious adverse experience related to valproic acid therapy.
Topics: Analysis of Variance; Antioxidants; Aspartate Aminotransferases; Child; Child Behavior Disorders; Ch | 1998 |
Valproic acid and risperidone.
Topics: Aggression; Antipsychotic Agents; Child; Child Behavior Disorders; Dose-Response Relationship, Drug; | 2001 |
American Academy of Pediatrics. Behavioral and cognitive effects of anticonvulsant therapy. Committee on Drugs.
Topics: Adult; Anticonvulsants; Attention; Carbamazepine; Child; Child Behavior Disorders; Clonazepam; Cogni | 1985 |